II. Class
III. Efficacy
- Good benefit in combination with 2 Nucleosides
IV. Dosing
- Start: 200 mg PO qd for 14 days
- If no rash, increase dose to 200 mg PO bid
V. Adverse effects
- See NNRTI for class related adverse effects
- Severe hepatoxicity and liver failure risk if pre-treatment CD4 >250 in men or >400 in women